Emtricitabine/rilpivirine/tenofovir disoproxil

Emtricitabine/rilpivirine/tenofovir disoproxil is a fixed-dose combination antiretroviral medication used in the treatment and prevention of HIV/AIDS. It combines three antiretroviral agents: emtricitabine, rilpivirine, and tenofovir disoproxil.

Composition

The medication is a combination of three drugs:

• Emtricitabine: A nucleoside reverse transcriptase inhibitor (NRTI) that interferes with the replication of the HIV virus.
• Rilpivirine: A non-nucleoside reverse transcriptase inhibitor (NNRTI) that also interferes with the replication of the HIV virus.
• Tenofovir disoproxil: Another NRTI that works in a similar way to emtricitabine.

Usage

Emtricitabine/rilpivirine/tenofovir disoproxil is used as part of combination therapy for the treatment of HIV-1 infection in adults and children who weigh at least 35 kg. It is also used as a pre-exposure prophylaxis (PrEP) to prevent HIV infection in people at high risk.

Side Effects

Common side effects include nausea, dizziness, insomnia, and abnormal dreams. Serious side effects may include liver problems, depression, and changes in bone mineral density.

Interactions

Emtricitabine/rilpivirine/tenofovir disoproxil can interact with other medications, including other antiretroviral drugs, antacids, and certain antibiotics and antifungal medications. It is important to discuss all medications and supplements with a healthcare provider before starting treatment.

See Also

• Antiretroviral therapy
• HIV/AIDS
• Pre-exposure prophylaxis